-+ 0.00%
-+ 0.00%
-+ 0.00%

Dong-A ST Wins Korean Approval for Type 2 Diabetes Combination Drug

PUBT·10/30/2026 07:47:04
Dong-A ST Wins Korean Approval for Type 2 Diabetes Combination Drug
  • Dong-A ST secured South Korean regulatory approval for Sugarempa, its type 2 diabetes combination treatment, on Oct. 30, 2026.
  • The approved formulations combine evogliptin 5 mg with empagliflozin 10 mg or 25 mg.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dong-A ST Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030800910), on October 30, 2026, and is solely responsible for the information contained therein.